Altoida Blog - Altoida

Positive lesions: tau hyperphosphorylation, beta-amyloid plaques, cerebral amyloid angiopathy, and glial responses
Negative lesions: neuronal loss and synaptic loss

Problem	Solutions
More financing is needed for candidate drugs	Further investment in neuroscience development
More patients are needed to participate in clinical trials	Ability to perform more decentralized neurological disease clinical trials
Need for better screening solutions in clinical trials	More sensitive biomarkers to reduce screening failure rate and identify patients who are a good fit
Need for improved data collection during drug trials to prove drug efficacy	More robust, granular data to assess small, intraindividual changes in neurocognitive function longitudinally

Altoida’s mission is to accelerate and improve drug development, neurological disease research, and patient care. To learn more about our precision-neurology platform and app-based medical device, contact us!